litlas
Log inCreate account

Jack A. Schalken

Active 1985–2024

131
Papers
21,431
Citations
87
h-index
129
i10-index

Citations

Citations per year for Jack A. Schalken1985: 1 citations1986: 5 citations1987: 7 citations1988: 14 citations1989: 11 citations1990: 25 citations1991: 38 citations1992: 38 citations1993: 79 citations1994: 75 citations1995: 61 citations1996: 73 citations1997: 93 citations1998: 82 citations1999: 90 citations2000: 129 citations2001: 147 citations2002: 109 citations2003: 128 citations2004: 125 citations2005: 124 citations2006: 115 citations2007: 137 citations2008: 170 citations2009: 174 citations2010: 203 citations2011: 177 citations2012: 198 citations2013: 224 citations2014: 206 citations2015: 175 citations2016: 205 citations2017: 181 citations2018: 122 citations2019: 481 citations2020: 479 citations2021: 494 citations2022: 333 citations2023: 249 citations2024: 356 citations2025: 175 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,023 citing papers, 25.6% of this breakdownChina: 717 citing papers, 9.1% of this breakdownUnited Kingdom: 501 citing papers, 6.3% of this breakdownGermany: 424 citing papers, 5.3% of this breakdownNetherlands: 393 citing papers, 5% of this breakdownCanada: 339 citing papers, 4.3% of this breakdownItaly: 335 citing papers, 4.2% of this breakdownFrance: 269 citing papers, 3.4% of this breakdownJapan: 240 citing papers, 3% of this breakdownSpain: 205 citing papers, 2.6% of this breakdownAustralia: 195 citing papers, 2.5% of this breakdownBelgium: 161 citing papers, 2% of this breakdown
0%25.6%Other 26.7%

Institutions

Fields

  • Medicine52.9%
  • Biochemistry, Genetics and Molecular Biology40.6%
  • Immunology and Microbiology1.3%
  • Engineering1.2%
  • Neuroscience0.9%
  • Chemistry0.8%
  • Other2.3%

Topics

  • Prostate Cancer Treatment and Research10.3%
  • Prostate Cancer Diagnosis and Treatment6.4%
  • Cancer-related molecular mechanisms research3.9%
  • Wnt/β-catenin signaling in development and cancer2.8%
  • Cancer Cells and Metastasis2.6%
  • RNA modifications and cancer2.3%
  • Other71.7%

Coauthors

All papers

Open in search
  1. Detection and localization of early- and late-stage cancers using platelet RNA

    Authors: Sjors G. J. G. In ‘t Veld, Mohammad Arkani, Edward P. Post, Mafalda Antunes‐Ferreira, Silvia D’Ambrosi, Daan C.L. Vessies, Lisa Vermunt, Adrienne Vancura, Mirte Muller, Anna-Larissa N. Niemeijer, Jihane Tannous, Laura L. Meijer, Tessa Y. S. Le Large, Giulia Mantini, Niels E. Wondergem, Kimberley M. Heinhuis, Sandra van Wilpe, J. Smits, Esther E.E. Drees, Eva Roos, Cyra E Leurs, Lee-Ann Tjon Kon Fat, Ewoud J. van der Lelij, Govert Dwarshuis, Maarten J. Kamphuis, Lisanne E. Visser, Romée Harting, Annemijn Gregory, Markus Schweiger, Laurine E. Wedekind, Jip Ramaker, Kenn Zwaan, Heleen Verschueren, Idris Bahce, Adrianus J. de Langen, Egbert F. Smit, Michel M. van den Heuvel, Koen J. Hartemink, Marijke J. E. Kuijpers, Mirjam G.A. oude Egbrink, Arjan W. Griffioen, Rafael Rossel, T. Jeroen N. Hiltermann, Elizabeth Lee-Lewandrowski, Kent Lewandrowski, Philip C. De Witt Hamer, Mathilde C.M. Kouwenhoven, Jaap C. Reijneveld, William P. J. Leenders, Ann Hoeben, Irma M. Verdonck‐de Leeuw, C. René Leemans, Robert J. Baatenburg de Jong, Chris H.J. Terhaard, Robert P. Takes, Johannes A. Langendijk, Saskia C.A. de Jager, Adriaan O. Kraaijeveld, Gerard Pasterkamp, Minke Smits, Jack A. Schalken, Sylwia Łapińska‐Szumczyk, Anna Łojkowska, Anna J. Żaczek, Henk M. Lokhorst, Niels W.C.J. van de Donk, Inger S. Nijhof, Henk‐Jan Prins, Josée M. Zijlstra, Sander Idema, Johannes C. Baayen, Charlotte E. Teunissen, Joep Killestein, Marc G. Besselink, Lindsay Brammen, Thomas Bachleitner‐Hofmann, Farrah J. Mateen, John Th. M. Plukker, Michal Heger, Quirijn de Mast, Ton Lisman, D. Michiel Pegtel, Harm Jan Bogaard, Jacek Jassem, Anna Supernat, Niven Mehra, Winald R. Gerritsen, Cor D. de Kroon, Christianne Lok, Jurgen M.J. Piek, Neeltje Steeghs, Winan J. van Houdt, Ruud H. Brakenhoff, Gabe S. Sonke, Henk M.W. Verheul, Elisa Giovannetti, Geert Kazemier, Siamack Sabrkhany, Ed Schuuring, Erik A. Sistermans and 16 more - Cancer Cell 2022 cited by 126

  2. Prevention and early detection of prostate cancer

    Authors: Jack Cuzick, Mangesh A. Thorat, Gerald L. Andriole, Otis W. Brawley, Powel H. Brown, Zoran Čulig, Rosalind A. Eeles, Leslie G. Ford, Freddie C. Hamdy, Lars Holmberg, Dragan Ilić, Timothy J. Key, Carlo La Vecchia, Hans Lilja, Michael Marberger, Frank L. Meyskens, Lori M. Minasian, Chris Parker, Howard L. Parnes, Sven Perner, Harry G. Rittenhouse, Jack A. Schalken, Hans Peter Schmid, Bernd J. Schmitz‐Dräger, Fritz H. Schröder, Arnulf Stenzl, Bertrand Tombal, Timothy J Wilt, Alicja Wolk - The Lancet Oncology 2014 cited by 492

  3. Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

    Authors: Sofie H. Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi, Edmond M. Kwan, Sarah W.S. Ng, Matti Annala, Gráinne Donnellan, Cameron Herberts, Guillemette E. Benoist, Paul Hamberg, Diederik M. Somford, Inge M. van Oort, Jack A. Schalken, Niven Mehra, Nielka P. van Erp, Alexander W. Wyatt - Clinical Cancer Research 2023 cited by 56

  4. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men

    Authors: Rianne J. Hendriks, Marloes M. G. van der Leest, Bas Israël, Gerjon Hannink, Anglita Yantisetiasti, Erik B. Cornel, Christina A. Hulsbergen‐van de Kaa, O.S. Klaver, J.P. Michiel Sedelaar, Wim Van Criekinge, Hans de Jong, Peter F.A. Mulders, E. David Crawford, Jeroen Veltman, Jack A. Schalken, Jelle O. Barentsz, Inge M. van Oort - Prostate Cancer and Prostatic Diseases 2021 cited by 82

  5. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker–Based Risk Score

    Authors: Leander Van Neste, Rianne J. Hendriks, Siebren Dijkstra, Geert Trooskens, Erik B. Cornel, Sander A. Jannink, Hans de Jong, Daphne Hessels, Frank Smit, Willem J. G. Melchers, G.H.J.M. Leyten, Theo M. de Reijke, H. Vergunst, Paul J.M. Kil, Ben C. Knipscheer, Christina A. Hulsbergen‐van de Kaa, Peter F.A. Mulders, Inge M. van Oort, Wim Van Criekinge, Jack A. Schalken - European Urology 2016 cited by 374

  6. PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

    Authors: John Dulos, Gregory J. Carven, Susan J. van Boxtel, Sabine Evers, Lilian J. A. Driessen-Engels, Willemijn Hobo, Monika Górecka, Anton F. J. de Haan, Peter F.A. Mulders, Cornelis J. A. Punt, Joannes F.M. Jacobs, Jack A. Schalken, Egbert Oosterwijk, Hans van Eenennaam, A. Boots - Journal of Immunotherapy 2012 cited by 318

  7. Liquid biopsy in bladder cancer: State of the art and future perspectives

    Authors: Felice Crocetto, Biagio Barone, Matteo Ferro, Gian Maria Busetto, Evelina La Civita, Carlo Buonerba, Giuseppe Di Lorenzo, Daniela Terracciano, Jack A. Schalken - Critical Reviews in Oncology/Hematology 2022 cited by 91

  8. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

    Authors: Marion J.G. Bussemakers, Adrie van Bokhoven, Gerald W. Verhaegh, Frank Smit, Herbert F.M. Karthaus, Jack A. Schalken, F.M.J. Debruyne, Ning Ru, William B. Isaacs - 1999 cited by 1,062

  9. Polyisocyanide Hydrogels as a Tunable Platform for Mammary Gland Organoid Formation

    Authors: Ying Zhang, Chunling Tang, Paul N. Span, Alan E. Rowan, Tilly Aalders, Jack A. Schalken, Gosse J. Adema, Paul H. J. Kouwer, Mirjam M. Zegers, Marleen Ansems - Advanced Science 2020 cited by 66

  10. DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer

    Authors: Daphne Hessels, Jacqueline M. T. Klein Gunnewiek, Inge M. van Oort, Herbert F.M. Karthaus, Geert J.L. van Leenders, Bianca van Balken, Lambertus A. Kiemeney, J. Alfred Witjes, Jack A. Schalken - European Urology 2003 cited by 702

  11. Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis

    Authors: Milena Matuszczak, Jack A. Schalken, Maciej Salagierski - Cancers 2021 cited by 70

  12. Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer

    Authors: Jack A. Schalken, John M. Fitzpatrick - British Journal of Urology 2015 cited by 144

  13. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions

    Authors: Rianne J. Hendriks, Inge M. van Oort, Jack A. Schalken - Prostate Cancer and Prostatic Diseases 2016 cited by 136

  14. Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer

    Authors: G.H.J.M. Leyten, Daphne Hessels, Sander A. Jannink, Frank Smit, Hans de Jong, Erik B. Cornel, Theo M. de Reijke, H. Vergunst, Paul J.M. Kil, Ben C. Knipscheer, Inge M. van Oort, Peter F.A. Mulders, Christina A. Hulsbergen‐van de Kaa, Jack A. Schalken - European Urology 2012 cited by 358

  15. 68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study

    Authors: Wim van Boxtel, Susanne Lütje, Ilse C.H. van Engen-van Grunsven, Gerald W. Verhaegh, Jack A. Schalken, Marianne A. Jonker, James Nagarajah, Martin Gotthardt, Carla M.L. van Herpen - Theranostics 2020 cited by 71

  16. Genomic Markers in Prostate Cancer Decision Making

    Authors: Vito Cucchiara, Matthew R. Cooperberg, Marc Dall’Era, Daniel W. Lin, Francesco Montorsi, Jack A. Schalken, Christopher P. Evans - European Urology 2017 cited by 281

  17. The use of PCA3 in the diagnosis of prostate cancer

    Authors: Daphne Hessels, Jack A. Schalken - Nature Reviews Urology 2009 cited by 237

  18. Consensus on molecular imaging and theranostics in prostate cancer

    Authors: Stefano Fanti, Silvia Minozzi, Gerald Antoch, Ian Banks, Alberto Briganti, Ignasi Carrió, Arturo Chiti, Noel W. Clarke, Matthias Eiber, Johann S. de Bono, Karim Fizazi, Silke Gillessen, Sam Gledhill, Uwe Haberkorn, Ken Herrmann, Rodney J. Hicks, Frédéric Lecouvet, Rodolfo Montironi, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Jack A. Schalken, Howard I. Scher, Bertrand Tombal, R. Jeroen A. van Moorselaar, Heindrik Van Poppel, Hebert Alberto Vargas, Jochen Walz, Wolfgang Weber, Hans‐Jürgen Wester, Wim J.G. Oyen - The Lancet Oncology 2018 cited by 118

  19. Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy

    Authors: Alexander Haese, Geert Trooskens, Sandra Steyaert, Daphne Hessels, Michael K. Brawer, Virginie Vlaeminck‐Guillem, A. Ruffion, Derya Tilki, Jack A. Schalken, Jack Groskopf, Wim Van Criekinge - The Journal of Urology 2019 cited by 100

  20. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies

    Authors: Emmy Boerrigter, Levi Groen, Nielka P. van Erp, Gerald W. Verhaegh, Jack A. Schalken - Expert Review of Molecular Diagnostics 2019 cited by 50

  21. Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide

    Authors: Guillemette E. Benoist, Rianne J. Hendriks, Peter F.A. Mulders, Winald R. Gerritsen, Diederik M. Somford, Jack A. Schalken, Inge M. van Oort, David M. Burger, Nielka P. van Erp - Clinical Pharmacokinetics 2016 cited by 104

  22. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1

    Authors: Ira Kogan-Sakin, Merav Cohen, Nicole Paland, Shalom Madar, Hilla Solomon, Alina Molchadsky, Ran Brosh, Yosef Buganim, Naomi Goldfinger, Helmut Klocker, Jack A. Schalken, Varda Rotter - Carcinogenesis 2009 cited by 87

  23. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review

    Authors: Maike J.M. Uijen, Gerben Lassche, Adriana C. H. van Engen–van Grunsven, Yuichiro Tada, Gerald W. Verhaegh, Jack A. Schalken, C.M.L. Driessen, Carla M.L. van Herpen - Cancer Treatment Reviews 2020 cited by 56

  24. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer

    Authors: Sofie H. Tolmeijer, Sandra van Wilpe, Maartje J. Geerlings, Daniel von Rhein, Tineke J. Smilde, Iris S. H. Kloots, Harm Westdorp, M. Coskuntürk, Irma M. Oving, Jolique A. van Ipenburg, Antoine G. van der Heijden, Tom Hofste, Marjan M. Weiss, Jack A. Schalken, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra - European Urology Oncology 2023 cited by 20